| Subject: | FDA Issues Notice About Depo-Provera and Bone Loss |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 7 Dec 2004 - 10:00 am |
| The FDA and Pfizer Inc., have issued a notification to healthcare professionals that there is evidence that long term use of Depo-Provera Contraceptive Injection may result in significant loss of bone mineral density. Depo-Provera (medroxyprogesterone acetate) is an injectable progestin-only reversible method of birth control, with the effect of the contraceptive lasting approximately twelve (12) weeks. The FDA reports that bone loss is greater with increased length of use, and the effects of... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
